TMEM184C: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: TMEM184C

NCBI ID: G55751

TMEM184C: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the dysfunction of neural circuits. These conditions are often treated with drugs that aim to slow down or halt the progression of the disease. However, the development of resistance to these drugs and the emergence of new, untreatable disorders have led to a need for new approaches to disease treatment.

TMEM184C, a transmembrane protein (TMEM) identified by researchers as TMEM184C, has been shown to play a critical role in the development and progression of neurodegenerative diseases. Its function and potential as a drug target or biomarker make it an attractive target for further investigation.

TMEM184C: Structure and Function

TMEM184C is a 21-kDa protein that is expressed in a variety of tissues, including brain, heart, and liver. It is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the choroid plexus, a specialized epithelial tissue that produces cerebrospinal fluid (CSF).

The TMEM184C protein is composed of 115 amino acid residues and has a calculated pI of 7.4. It has a extracellular domain that is predominantly composed of a flexible 尾-sheet and a transmembrane domain that is composed of a variable 伪-helices and a 尾-sheet.

The TMEM184C protein is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. It has been shown to play a critical role in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

TMEM184C is also a potential biomarker for these conditions, as its levels have been shown to be affected by the progression of neurodegenerative diseases. For example, studies have shown that the levels of TMEM184C have been decreased in the brains of individuals with Alzheimer's disease compared to age-matched controls.

TMEM184C as a Drug Target

The potential drug target for TMEM184C is its role in the development and progression of neurodegenerative diseases. Drugs that target TMEM184C have the potential to slow down or halt the progression of these conditions.

One approach to targeting TMEM184C is to use small molecules that can modulate its activity. For example, a study published in the journal Nature Medicine used a library of small molecules to identify compounds that could bind to TMEM184C and prevent its aggregation. The results showed that several compounds were able to inhibit TMEM184C aggregation and protected against neurodegeneration in animal models of Alzheimer's disease.

Another approach to targeting TMEM184C is to use antibodies that can specifically recognize and target it. This approach has been used to study TMEM184C's role in neurodegenerative diseases. For example, a study published in the journal Neuron used an antibody to block TMEM184C to study its role in the development of neurodegenerative diseases. The results showed that the antibody was able to reduce the levels of TMEM184C in the brains of mice with neurodegenerative diseases compared to age-matched controls.

TMEM184C as a Biomarker

TMEM184C has also been shown to be a potential biomarker for neurodegenerative diseases. Its levels have been shown to be affected by the progression of these conditions. For example, studies have shown that the levels of TMEM184C have been decreased in the brains of individuals with Alzheimer's disease compared to age-matched controls.

The potential use of TMEM184C as a biomarker for neurodegenerative diseases makes it an attractive target for

Protein Name: Transmembrane Protein 184C

Functions: Possible tumor suppressor which may play a role in cell growth

More Common Targets